Breast Cancer | Specialty

Expert Highlights Immunotherapy/Chemotherapy Combos in TNBC

October 31st 2018

The efficacy of combination therapy with a checkpoint inhibitor and chemotherapy has been proved in the triple-negative breast cancer space, and the additive and early toxicity may be worth the survival benefit, according to Lisa A. Carey, MD.

Rugo Relays Next Wave of Developments in HR+ Breast Cancer

October 30th 2018

Hope S. Rugo, MD, discusses CDK4/6 inhibition in HR-positive breast cancer, mechanisms of resistance to these drugs, and other potential pathway blockades.

Expert Discusses MINDACT, TAILORx Studies in Breast Cancer

October 29th 2018

Michelle E. Melisko, MD, discusses the clinical implications of the TAILORx and MINDACT studies.

Benefit of Extended Adjuvant Endocrine Therapy Remains Unknown

October 29th 2018

In a presentation during an OncLive® State of the Science Summit™, Melanie Majure, MD, discussed the duration of endocrine-directed therapy for estrogen receptor–positive breast cancer.

Immunotherapy Breaks Through in Breast Cancer

October 27th 2018

Peter Schmid, MD, PhD, shares the results of IMpassion130 and discussed his thoughts on the future of immunotherapy in breast cancer.

Breast Cancer Expert Highlights Potential for Liquid Biopsies

October 26th 2018

Joseph A. Sparano, MD, discusses the potential for liquid biopsy and the ongoing challenge of improving survival for patients with metastatic breast cancer.

Dr. Schmid Discusses the Findings of the IMpassion130 Trial in TNBC

October 23rd 2018

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Dr. Andre on the Impact of the SOLAR-1 Findings in Breast Cancer

October 21st 2018

Fabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018

ESMO 2018: Dr. Cohen Reflects on Practice-Changing Data in Head and Neck Cancer

October 21st 2018

ESMO 2018: Dr. George Highlights Key Abstracts in Kidney and Prostate Cancers

October 21st 2018

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Alpelisib Combo Nearly Doubles PFS in PIK3CA-Mutant Breast Cancer

October 21st 2018

The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

OS Benefit Confirmed With Palbociclib Combo in Pretreated HR+/HER2- Breast Cancer

October 21st 2018

The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.